Latest Breaking News On - Hans vitzthum - Page 18 : comparemela.com

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesVastra gotalands lanColleen alabisoLance buckleyHans vitzthumAlbireo pharma incLifesci advisorsNasdaq listing ruleEquity incentiveOpen label extensionAlbireo pharma

Albireo Pharma, Inc (ALBO) CEO Ron Cooper on Q2 2022 Results - Earnings Call Transcript

Albireo Pharma, Inc. (NASDAQ:NASDAQ:ALBO) Q2 2022 Earnings Conference Call August 15, 2022, 16:30 ET Company Participants Hans Vitzthum - LifeSci Advisors Ron Cooper - CEO, President &.

United statesUnited kingdomEd arceAndreas argyridesHans vitzthumRon cooperJan mattssonLachlan hanbury brownAcceleron pharmaBrian skorneyEun yangPamela stephensonTim lugoSimon harfordAsia pacificSusan alesina

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

09.08.2022 - - FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS - On track to report initial Phase 1 clinical data for FHD-609 in synovial .

United statesUnited kingdomKarin hellsvikMichael lampeAdrian gottschalkHans vitzthumFoghorn therapeutics incDrug administrationCompany annual report on formDevelopment expensesExchange commissionTherapeutics incGene traffic control platformBalance sheetLilly collaboration agreementGene traffic control

Foghorn Therapeutics : Provides Second Quarter 2022 Financial and Corporate Update - Form 8-K

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update -FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues. | August 9, 2022

United statesUnited kingdomKarin hellsvikMichael lampeAdrian gottschalkHans vitzthumFoghorn therapeutics incDrug administrationExchange commissionCompany annual report on formDevelopment expensesTherapeutics incFoghorn therapeutics provides second quarterCorporate updateGene traffic controlMerck collaboration

Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Second Quarter Glaucoma Franchise Net Revenues of $33.3 Million, up 23% over Second Quarter 2021Outlook for Net Cash Used Expected to Be Less Than $20 Million per Quarter, on Average, for the Remainder of 2022 Aerie Expects to be Cash Flow Break Even During 2024DURHAM, N.C.DURHAM, N.C. (BUSINESS WIRE) Aerie Pharm.

United statesRaj kannanHans vitzthumCarolyn mcauliffeAerie pharmaceuticals incDrug administrationRegulatory agencyExchange commissionEuropean medicines agencyAerie pharmaceuticalsSecond quarter glaucoma franchise net revenuesSecond quarterNet cash used expectedCash flow break even duringChief executive officerQuarter financial results